Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
FDA Leadership Regulation

Pink Sheet Podcast: US FDA Commissioner Nominee Stephen Hahn Appears Before The Senate, Controversial Regulations In The New Unified Agenda

  • Analysis

Executive Summary

Pink Sheet reporters explain Stephen Hahn's responses to Senators' questions and discuss some of the new regulations that FDA plans to release in the coming months.

You may also be interested in...



Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.

Keeping Track: Vascepa Adds CV Risk Reduction Claim, Vyondys 53 Get A Stunning Approval, And Submissions Pour Into FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Stephen Hahn Takes US FDA Helm Under Cloud Of Doubt About Vaping Stance

HELP Committee ranking member Patty Murray said because of Hahn's evasive responses to questions about curbing youth e-cigarette use during committee meeeting, she would oppose his confirmation. She also said she was not convinced Hahn would uphold FDA standards.
Table

View full table

Topics

Tags:
FDA Leadership Regulation
UsernamePublicRestriction

Register

PS141248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By